Oncology & Cancer

Lymphoma cell metabolism may provide new cancer target

Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves, according to a study ...

Medications

Axicabtagene ciloleucel slows large B-cell lymphoma

(HealthDay)—For patients with refractory or relapsed large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) leads to improvements in event-free survival and response compared with standard care, according to a study published ...

Medications

New hope for patients with relapsed large B-cell lymphoma

Of the 18,000 people diagnosed with large B-cell lymphoma each year, only half will be successfully treated with chemotherapy. The 9,000 remaining patients typically have poor outcomes, with only 25% responding to additional, ...

Oncology & Cancer

Thanks to clinical trials, big leaps made in lymphoma treatment

Newer therapies are outpacing the current treatment for diffuse large B cell lymphoma, according to data that scientists will deliver from two major clinical trials at the American Society of Hematology (ASH) annual meeting ...

Oncology & Cancer

Receptor structure reveals new targets for cancer treatment

A molecule known as anaplastic lymphoma kinase (ALK) is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors. But for years much about this molecule—its role in the ...

Oncology & Cancer

Understanding the tricks of lymphomas

Cellular immunotherapies have so far not been very effective against non-Hodgkin's lymphoma. A team led by Armin Rehm of the MDC has discovered a possible reason. As the they describe in Cell Reports, this cancer induces ...

page 1 from 38